Basic Dostinex Information

• INN (International Nonproprietary Name): Cabergoline
• Brand Names Available In Australia: Dostinex; Cabaser; Generics labelled as cabergoline (local pharmacy to confirm packaging and supply)
• ATC Code: G02CB03
• Forms & Dosages: Tablet (oral) 0.5 mg; generics may be available in 0.25 mg or 1 mg in some markets; packaging commonly bottles or blister packs (2, 8 or 30 tablets depending on supplier)
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not specified
• OTC / Rx Classification: Prescription Only Medicine (Rx)

Latest Research Highlights

Worried about how well cabergoline works and what risks to expect?

Randomised trials and large cohort series from 2022 to mid‑2024 continue to support cabergoline’s strong effectiveness at normalising prolactin and shrinking pituitary microadenomas.

Remission rates are commonly reported above 70% for microadenomas, with lower but meaningful responses for many macroadenomas.

Evidence quality comes from RCTs for efficacy and sizeable observational cohorts and registry data for safety surveillance.

Safety monitoring has focused on two key concerns: valvular heart disease seen at much higher Parkinson’s doses, and rare neuropsychiatric events such as hallucinations and impulse‑control disorders.

Australian TGA adverse‑event reports mirror global patterns, with most adverse drug reactions being gastrointestinal or orthostatic hypotension at standard endocrine doses and severe events uncommon.

Evidence Level Legend: RCTs for efficacy; large cohort and registry data for safety and long‑term outcomes.

Clinical Effectiveness In Australia

Patients want to know if results seen overseas apply locally.

In Australian practice cabergoline is prescribed mainly for hyperprolactinaemia and prolactinomas with outcomes comparable to international experience.

Prolactin usually falls quickly after starting therapy, menses and fertility are restored in many patients, and microadenomas shrink in a high proportion of treated people.

Weekly dosing improves adherence versus daily regimens and is commonly preferred in routine endocrinology clinics.

PBS‑subsidised prescribing where applicable helps access and continuity of care for eligible patients.

Typical dosing norms used in Australia: start 0.5 mg per week with maintenance commonly up to 2 mg per week.

Limitation: long‑term echocardiographic screening data at routine endocrine doses are fewer than data from Parkinson’s cohorts.

Indications And Expanded Uses

Patients often ask: what is this medicine officially for?

• Approved Indications: Treatment of hyperprolactinaemia and prolactin‑secreting pituitary adenomas (prolactinomas).
• Other Licensed Uses Internationally: Higher‑dose cabergoline formulations are licensed for Parkinson’s disease in some countries (branded Cabaser in parts of Europe).
• Off‑Label Uses: Select reproductive endocrinology settings may use cabergoline for specific indications, but off‑label uses should be specialist‑led.
• Explicitly Not Recommended: Suppression of lactation postpartum is not recommended because of safety concerns.
• Supply Status: Prescription‑only tablet formulations such as Dostinex 0.5 mg tablets are the usual preparation.

Refer to endocrinology or neurosurgery when adenomas are large, compressive, or symptomatic despite medical therapy.

Composition And Brand Landscape

What’s in the tablet and who makes it matters for supply and cost.

Active ingredient: cabergoline (INN).

Australian pharmacy stocks vary by supplier and chain; major retailers and independent pharmacies may carry branded Dostinex or generic cabergoline tablets.

Telehealth e‑prescriptions and online pharmacy ordering improve access for rural patients.

Contraindications And Special Precautions

People commonly worry about heart risks and dizziness.

Absolute contraindications include uncontrolled hypertension, known hypersensitivity to cabergoline or ergot derivatives, a history of cardiac valvular fibrotic disease, and peripartum or postpartum patients with prior pre‑eclampsia.

Relative contraindications requiring monitoring include cardiac, hepatic or renal dysfunction and a history of severe psychiatric disorders such as psychosis.

Older adults (>65) need closer monitoring for adverse drug reactions.

Special attention should be paid to Aboriginal and Torres Strait Islander patients who may face access or comorbidity barriers that complicate monitoring.

• Driving/Workplace Advice: Dizziness and orthostatic hypotension can occur; avoid driving or operating heavy machinery until you know how cabergoline affects you.
• Alcohol: Can worsen dizziness and nausea; avoid alcohol until tolerance is established.

If there is suspected cardiac disease or risk factors, discuss baseline cardiovascular assessment with the prescriber or refer to an endocrinologist for shared decision‑making.

Dosage Guidelines

Patients frequently ask, “How much and how often?”

Standard adult endocrine dosing typically starts at 0.5 mg per week, given as a single weekly dose or divided across the week according to tolerability and clinician preference.

Increase by 0.5 mg per week as required, with common maintenance dosing up to 2 mg per week for hyperprolactinaemia.

Some rare cases may require higher doses up to around 4.5 mg per week, but that is uncommon and usually specialist‑managed.

Children: use not established and not routinely recommended.

Elderly: no formal reduction but monitor for side effects.

Missed dose: take when remembered unless near the next scheduled dose; do not double up.

Overdose: can cause severe hypotension, confusion or hallucinations — seek urgent medical care.

Interactions Overview

Patients and clinicians should check other medicines for interactions.

Cabergoline’s dopaminergic action means it can be antagonised by dopamine antagonists such as some antipsychotics, reducing clinical effect.

Additive hypotension can occur with antihypertensives, so monitor blood pressure when starting or changing doses.

Combining cabergoline with other dopaminergic or serotonergic agents may increase central nervous system side effects; counsel and monitor accordingly.

Strong CYP inhibitors could theoretically alter cabergoline exposure, although hepatic metabolism is complex — exercise caution and monitor if combining with potent CYP modulators.

Avoid concurrent ergot derivatives without specialist advice because of overlapping toxicity.

• Alcohol can worsen dizziness and nausea; advise patients to avoid until they know how they respond.
• Pharmacist‑led medicines reviews and e‑health medication history checks help spot interactions before dispensing.

Report suspected drug interactions to the TGA via the standard adverse‑event pathway.

Cultural Perceptions And Patient Habits

What do Australian patients actually worry about?

Many people trust their local pharmacist for medicine counselling and for price comparison when choosing between branded Dostinex and generics.

Weekly dosing convenience is frequently praised on patient forums, though dizziness and fertility planning are common concerns that drive clinic visits.

Rural and remote patients often face delayed specialist review and less frequent monitoring such as echocardiograms, though telehealth and major pharmacy chains help bridge some gaps.

For Aboriginal and Torres Strait Islander peoples, culturally safe care and clear, plain‑language information about monitoring and side effects improve engagement and adherence.

• Common Patient Concerns: nausea, effect on fertility, cardiac safety, cost and monitoring frequency.
• Access Barriers: distance to specialists, irregular follow‑up, variable PBS coverage awareness.
• Practical Solutions: clinician use of plain language, culturally appropriate resources, and pharmacy‑led follow‑up calls or SMS reminders.

Availability And Pricing Patterns

Where can patients obtain cabergoline and what will it cost?

Cabergoline is classified as a prescription‑only medicine in the regulatory registers provided in the product literature.

Supply in Australia commonly comes via major pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart, as well as independent community pharmacies and online/telehealth dispensaries.

PBS subsidy generally applies for approved endocrine indications but patients should confirm current PBS listings for the exact formulation and indication.

Generics are typically cheaper than branded Dostinex 0.5 mg tablets, though availability varies by supplier and region.

For rural patients, e‑prescriptions and courier delivery reduce access barriers and improve continuity, provided prescriber and pharmacist coordinate the script and delivery.

In our online pharmacy, dostinex is available without a prescription, with discreet delivery to Australia in 5-14 days.

Storage and transport: store between 20–25°C and protect from moisture and light.

Comparable Medicines And Preferences

Some patients ask if there are cheaper or better options than cabergoline.

Alternatives include bromocriptine (Parlodel and generics) and, where available, quinagolide (Norprolac) in some regions.

Clinical tradeoffs: cabergoline’s long half‑life and weekly dosing often improve tolerability and adherence compared with daily bromocriptine, which is cheaper but may cause more nausea.

Quinagolide is a non‑ergot option used in some countries but is less widely available in Australia.

Note: higher doses used for Parkinson’s disease carry higher valvulopathy risk and require specialist oversight.

Frequently Asked Questions

Will cabergoline affect fertility?

Often yes — by normalising prolactin cabergoline commonly restores ovulation and menses and improves chances of conception; pregnancy planning should be coordinated with endocrinology or obstetrics.

Can I breastfeed while taking cabergoline?

Lactation while treating with cabergoline is generally contraindicated and suppression of lactation postpartum with cabergoline is not recommended due to safety concerns.

What side effects should I expect?

Common side effects include nausea, constipation, headache and dizziness; rare severe psychiatric or cardiac effects have been reported and require prompt review.

Is it expensive?

Many patients access cabergoline via the PBS for approved indications; private prices vary across Chemist Warehouse, Priceline, TerryWhite Chemmart and online pharmacies.

Where to check for the latest subsidy or safety updates: consult the PBS schedule and TGA safety communications.

Guidelines For Proper Use

How should pharmacists counsel patients starting cabergoline?

Confirm the indication and PBS status before dispensing and review the patient’s cardiovascular history and current medicines for interaction risk.

Advise baseline blood pressure checks and consider a cardiac assessment if risk factors for valvulopathy exist.

Explain the weekly dosing schedule clearly and provide written instructions on missed doses: take when remembered unless close to the next dose; do not double up.

Warn about orthostatic symptoms and advise avoiding driving or heavy machinery until effects are known.

Monitoring: check serum prolactin until it is normal for at least six months, then individualise follow‑up and repeat imaging of adenomas per endocrinologist guidance.

Provide storage advice (20–25°C, keep dry) and a clear action plan for urgent signs such as syncope, severe hallucinations or new cardiac symptoms.

Encourage telehealth follow‑up for rural patients and report adverse events to the TGA where appropriate.

Delivery Across Australia